

17th International Conference on Progress in Vaccination Against Cancer



27 - 30 September 2017

Loutraki, Corinth, Greece

Scientific Organising Committee

Costas Baxevanis (Chair) • Graham Pawelec

Per Thor Straten • Victor Umansky • Sonia Perez

PIVAC-16

17th International Conference

Progress in Vaccination Against Cancer

27 – 30 September 2017 • Loutraki, Corinth, Greece



Day 1 – Wednesday 27 September 2017

13.00 – 20.00 **REGISTRATION** *Entrance Lobby of the Alexandrion Conference Hall*

13.00 – 14.30 **WELCOME LUNCH**

13.00 – 20.45 **POSTER EXHIBITION**

15.00 – 15.15 **WELCOME BY THE MAJOR OF LOUTRAKI**

George Gionis

WELCOME BY THE PIVAC-17 CHAIR

Costas Baxevanis Cancer Immunology and Immunotherapy Center, St Savas Hospital (GR)

SESSION 1

Session Chair:

15.15 – 15.45 **Per thor Straten** Center for Cancer Immune Therapy, Department of Hematology, University Hospital Herlev
“**Therapy of solid tumors using T cells and running shoes**”

15.45 – 16.15 **Rolf Kiessling** Karolinska Institutet, CCK, Stockholm, Sweden
“**Combining Adoptive Cell Therapy with DC vaccination for therapy of malignant melanoma**”

16.15 – 16.45 **Rafael Solana** Maimonides Biomedicine Institute of Cordoba (IMIBIC), Reina Sofia Hospital, University of Cordoba
“**New insights on NK cell-based immunotherapy of cancer**”

16.45 – 17.15 **COFFEE BREAK**

SESSION 2

Session Chair:

17.15 – 17.45 **Barbara Seliger** Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle
“**Tumor-induced immune escape mechanisms due to deregulation of immune relevant components**”

17.45 – 18.15 **Federico Garrido** Departamento de Bioquímica, Biología Molecular III e Inmunología, Facultad de Medicina, Universidad de Granada
“**Rejection versus escape: the tumour-MHC dilemma**”

18.15 – 19.45 **POSTER SESSION 1**

20.00 - **WELCOME RECEPTION** serving drinks and a light buffet

Day 2 - Thursday 28 September 2017

08.30 – 09.00

COFFEE

SESSION 3

Session Chair:

09.00 – 09.30

Giuseppe Masucci Department of Oncology-Pathology, The Karolinska Hospital, Stockholm
"Prognostic factors and Immunoscore in personalized cancer treatment"

09.30 – 10.00

Francesco Marincola Division of Translational Medicine, Research Branch, Sidra Medical and Research Center, Doha
"Markers of cancer immune responsiveness"

10.00 – 10.30

Wolf Herve Fridman INSERM Paris, France; Université Paris Descartes/Paris V, Sorbonne
Paris Cité, Paris "Cancer microenvironments: prognostic and theranostic impacts"

10.30 – 11.00

Doriana Fruci Immuno-Oncology Laboratory, Ospedale Pediatrico Bambino, Rome
"Clinical relevance of tumor-infiltrating immune cells in neuroblastoma"

11.00-11.30

COFFEE BREAK

SESSION 4

Session Chair:

11.30 – 12.00

Gustav Gaudernack Department of Immunology, Institute for Cancer Research,
University Hospital-Radiumhospitalet, Oslo
"Clinical trials with a second generation hTERT vaccine, UV1. Single agent
therapy and combination with checkpoint inhibitors"

12.00 – 12.30

Sjoerd van der Burg Leiden University Medical Center
"Cancer Immunotherapy, not without vaccination"

12.30 – 13.00

Carl Figdor Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen
"21st Century Cancer Vaccines"

13.00-13.30

COFFEE BREAK

SESSION 5

Session Chair:

13.30 – 14.00

Federica Cavallo
Molecular Biotechnology Center, University Turin
"Fighting breast cancer stem cells through the
immune-targeting of the xCT antiporter system"

14.00 – 14.30

Pierre Coulie de Duve Institute, Université Catholique de Louvain, Brussels
"Immunogenicity of primary breast carcinomas"

14.30 – 15.00

Paul Lehmann Case Western Reserve University, USA
"Tumor antigen recognition by healthy individuals and cancer patients"

15.00 – 16.30

LUNCH

SESSION 5

Session Chair:

Proffered Papers

16.30 – 18.00	Proffered Papers 1-6
18.00-18.30	COFFEE BREAK
18.30 – 19.30	Proffered Papers 7-10
19.30 – 20.30	POSTER SESSION 2
20.30 –	Free evening

Day 3 - Friday 29 September 2017

08.30 – 09.00	COFFEE SESSION 6 Session Chair:
09.00 – 09.30	Victor Umansky Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg “Accumulation of myeloid-derived suppressor cells in melanoma microenvironment and their targeting”
09.30 – 10.00	Vincenzo Bronte Department of Medicine, University Hospital, University of Verona, Verona “Myeloid cells assist tumor progression by molecular mechanisms either dependent or independent from adaptive immunity”
10.00 – 10.30	Suzanne Rosenberg Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD “The good, the bad, and the in-between: immune suppression, obesity, and tumor progression”
10.30 – 11.00	Vincenzo Cerundolo Department of Medicine, University Hospital, University of Verona, Verona “Ability of the tumour micro-environment to hamper tumour specific immune response”
11.00-11.30	COFFEE BREAK SESSION 7 Session Chair:
11.30 – 12.00	Ignacio Melero Division of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra and Instituto de Investigacion Sanitaria de Navarra “On combined strategies of cancer immunotherapy based on CD137 (4-1BB)”
12.00 – 12.30	Nathan Karin Department of Immunology, The B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa “CXCL10 as an immune checkpoint chemokine in the regulation of cancer diseases”
12.30 – 13.00	Benoit van den Eynde Ludwig Institute for Cancer Research, Oxford Title TBA
13.00-13.30	COFFEE BREAK SESSION 8 Session Chair:

13.30 – 14.00	Gunter Hammerling Division of Molecular Immunology, German Cancer Research Center Heidelberg Reprogramming of the tumor microenvironment for efficient cancer immunotherapy
14.00 – 14.30	Graham Pawelec Second Department of Internal Medicine, University of Tübingen “Immunotherapy of Cancer: triumphs and challenges, and the impact of immunosenescence”
14.30 – 15.00	Cornelis Melief Department of Immunohematology and Blood Transfusion, Leiden University Medical Center “Combination immunotherapy against cancers expressing viral or neo-antigens”
15.00 – 16.30	LUNCH SESSION 9 Session Chair:
16.30 – 17.00	Gosse Adema Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen “Immuno-combination therapies for cancer”
17.00 – 17.30	Antonia Dimitrakopoulou-Strauss Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg “Therapy monitoring of immune checkpoint inhibitors in patients with metastatic melanoma with PET-CT”
17.30 – 18.00	Cecile Gouttefangeas , Group leader at the Institute for Cell Biology, Department of Immunology, Tübingen, “Immunomonitoring as a tool to identify biomarkers predicting the outcome of immunotherapy-treated patients”
18.00 – 19.30	Cancer Immunology and Immunotherapy editorial board meeting

Saturday 30 September 2017

Free day – *Excursion to Epidaurus old theater, Ancient Mycenae, Nafplion*

The organisers wish to express their appreciation for the significant support provided by sponsors at the **17th International Conference on Progress in Vaccination Against Cancer**. Their interest and enthusiasm for the meeting has enabled the organizers to provide an impressive scientific programme.

Premium Sponsor



Meeting Sponsors

